A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis Clinical Trial

Official title:

A Phase Ⅱ Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05496894
• Other study ID #: HE071-CSP-030
• Status: Withdrawn
• Phase: Phase 2
• Start date: August 2022
• Est. completion date: November 8, 2022

Study information

• Verified date: December 2022
• Source: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, single-arm, open-label Phase II study to evaluate the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with different doses in participants with Relapsing Multiple Sclerosis. Participants will be randomly enrolled into three treatment groups: Mitoxantrone Hydrochloride Liposome Injection 4 mg/m^2 group, Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 group, and Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 group. The primary outcome measure is the cumulative number of new Gd-enhancing lesions at the end of 48 weeks of Mitoxantrone Hydrochloride Liposome Injection treatment in brain MRI.

Description:

Multiple sclerosis is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS) and is one of the most common causes of neurological disability in young adults. It is characterised by multi-focal recurrent attacks of neurological symptoms and signs with variable recovery.This is a multicenter, randomized, single-arm, open-label Phase II study to evaluate the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with different doses in participants with Relapsing Multiple Sclerosis. Participants will be randomly enrolled into three treatment groups: Mitoxantrone Hydrochloride Liposome Injection 4 mg/m^2 group, Mitoxantrone Hydrochloride Liposome Injection 8 mg/m^2 group, and Mitoxantrone Hydrochloride Liposome Injection 12 mg/m^2 group. The primary outcome measure is the cumulative number of new Gd-enhancing lesions at the end of 48 weeks of Mitoxantrone Hydrochloride Liposome Injection treatment in brain MRI.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 8, 2022
• Est. primary completion date: November 8, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• 18 to 55 years of age (inclusive);

• Diagnosis of relapsing multiple sclerosis (RMS);

• Disease duration of secondary progressive multiple sclerosis (SPMS) with superimposed relapses = 5 years;

• Expanded disability status scale (EDSS) score of 3 to 8;

• Participants who have received disease-modifying therapy still relapse or aggravate; or participants who, in the opinion of the investigator, are suitable for treatment with Mitoxantrone Hydrochloride Liposome Injection;

• Participants voluntarily sign informed consent, and complete the study according to the protocol.

Exclusion Criteria:

• Pregnant or lactating female participants or participants planning to have a child during the study;

• History of severe drug allergy, or allergy or intolerance to gadolinium, anthracyclines or liposome drugs;

• History of vitamin B12 deficiency;

• Participants with malignant tumor diagnosed within 5 years before the screening phase, except the skin basal cell carcinoma under effective control, and Stage I Squamous Cell Carcinoma);

• Participants with history of interstitial lung disease or with pneumonia according to chest X-ray in the screening phase;

• Participants with serious or active skin diseases, or clinically significant skin abnormalities in physical examination in the screening phase;

• History of severe immunodeficiency;

• History of drug and/or alcohol abuse, or mental disorder;

• Participants has a progressive neurological disorder or optic neuritis other than MS; or has other disease that should be treated more preferentially than MS, or that could interfere with the study or compromise participants compliance with treatment;

• MRI before randomization shows cervical spinal cord compression or lesions in non-MS characteristic areas of the brain, and the lesions can explain the changes in clinical symptoms and signs;

• MS relapse in the screening phase;

• Participated in other drug clinical studies and received investigational product within 3 months before screening or within 5 half-lives of the investigational product (whichever was longer), or participated in medical device clinical studies which is judged by the investigator to have a possible impact on the results of this study;

• Participants who have received disease-modifying therapy or immunosuppressive agents or systemic corticosteroids within the washout period before the first dose (e.g., 4 weeks for interferon, PEGylated interferon, glatiramer acetate, dimethyl fumarate and 12 weeks for fingolimod, siponimod, intravenous immunoglobulin or plasma exchange, etc.)

• Participants who have received anthracyclines or cardiotoxic drugs before screening;

• Participants who previously received total body irradiation or total lymphatic irradiation, or received stem cell therapy or any type of bone marrow transplantation, or received solid organ transplantation;

• Presence of the following clinically significant diseases: myocardial infarction, acute coronary syndrome, viral myocarditis, pulmonary embolism within 6 months; coronary revascularization within 6 months; arrhythmia requiring Class Ia or ? antiarrhythmic drugs;

• Laboratory tests in screening phase, such as white blood cell count, neutrophil count, platelet count, hemoglobin, creatinine clearance, etc., are abnormal with clinical significance (according to the judgment of the investigator); positive results for Hepatitis B Surface Antigen (HBsAg), Hepatitis C Antibody (HCVAb), syphilis antibody test; total bilirubin > 1.5x ULN, or alanine aminotransferase or aspartate aminotransferase > 3x ULN;

• Participants could not complete MRI scan before randomization, such as participants with claustrophobia;

• Participants with active or uncontrolled infection (defined as requiring systemic anti-infective therapy and the temperature = 38? (axillary temperature) before receiving drugs and unexplainable);

• Investigator believe that participants have other disease that are not suitable for participating in this study.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Relapsing Multiple Sclerosis
• Sclerosis

Intervention

Drug:
• Mitoxantrone Hydrochloride Liposome Injection
IV, once every 3 months (Q3M)

Locations

Country	Name	City	State
China	Xuanwu Hospital Capital Medical University	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The cumulative number of new Gadolinium (Gd)-enhancing lesions at the end of 48 weeks of Mitoxantrone Hydrochloride Liposome Injection treatment in brain MRI.		Week 48
Secondary	Annualized Relapse Rate (ARR)	ARR at Week 48 is calculated as the ratio of the sum of all participants confirmed relapse counts divided by the sum of all participants treatment duration (in years).	Week 48
Secondary	Number of Relapses		Week 48
Secondary	Time to Onset of Confirmed Disability Progression for at least 6 Months		Week 48
Secondary	Time to Onset of Confirmed Disability Progression for at least 3 Months		Week 48
Secondary	Proportion of participants with = 20% improvement from baseline in T25FW walking speed.		Week 48
Secondary	Change from baseline to Week 48 in T25FW walking speed.		Week 48
Secondary	Number of new or enlarged T2 lesions.		Week 48
Secondary	Change from baseline in brain MRI Gd-enhancing T1 lesion volume at Weeks 12?24?36?48.		Week 12?24?36?48
Secondary	Change from baseline in brain MRI T2 lesion volume at Weeks 12?24?36?48.		Week 12?24?36?48
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0		Week 56
Secondary	Plasma concentration of Mitoxantrone Hydrochloride Liposome Injection.		Week 12
Secondary	Descriptive analysis of the rate of change in the number or proportion of B cells from baseline to different time points in different dose groups.		Week 36
Secondary	Descriptive analysis of the rate of change in the number or proportion of T cells from baseline to different time points in different dose groups.		Week 36
Secondary	Descriptive analysis of the rate of change in the number or proportion of NK cells from baseline to different time points in different dose groups.		Week 36